Episode 183 - May 15, 2026

What It Covers

Biotech Hangout Episode 183 covers Bristol Myers Squibb's $950M upfront deal with Hengrui, China's growing competitive threat to US biotech innovation, Isomorphic Labs' $2.25B Series B raise, FDA Commissioner Marty Makary's resignation, and upcoming data catalysts at ASCO, ADA, and ATS conferences across oncology and respiratory disease.

Key Questions Answered

• •China Deal Structure: Bristol Myers Squibb's Hengrui agreement—$600M upfront, $175M at year one, $175M at year two, totaling $950M with $15.2B in potential milestones—introduces an unusual provision granting Hengrui co-development rights and global commercialization options. Investors tracking China-pharma partnerships should monitor whether this structure becomes a template, as it signals Chinese biotechs shifting from regional licensors to global commercial entities within a three-to-five year horizon.
• •China Innovation Risk Window: China's current competitive advantage in drug development rests on speed, scale, and cost—not yet on zero-to-one innovation. US biotechs retain a window of roughly five to ten years where licensing Chinese assets remains value-accretive. Companies should proactively develop a China strategy now, including evaluating whether to partner for early clinical development in China to accelerate proof-of-concept timelines before the cost and speed gap narrows further.
• •AI Drug Discovery Valuation Gap: Isomorphic Labs raised $2.25B in a Series B—following a $579M raise just two months prior—without visible biotech specialist investors, reflecting a tech-sector valuation mindset. Biotech investors should distinguish between platform technology value, where AlphaFold demonstrates real utility, and drug development value, where no tech-led company has yet bridged the gap from computational platform to approved commercial asset.
• •FDA Leadership Uncertainty: Makary's resignation creates regulatory gray-zone risk primarily for drugs reviewed under CBER, where smaller patient populations make efficacy evidence less definitive and approval decisions more judgment-dependent. Investors in accelerated approval candidates, rare disease programs, and single-arm trial assets should reassess timelines and approval probability assumptions until a confirmed, credentialed replacement commissioner is in place and review philosophy is established.
• •DMD Regulatory Precedent Trap: REGENXBIO's microdystrophin gene therapy showed correlation between expression levels and NSAA functional scores in nine patients, meeting its primary endpoint and targeting a 2027 accelerated approval filing. However, Sarepta's Elevidys approval has created a precedent problem—regulators face pressure to approve mechanistically similar therapies regardless of comparative efficacy. Investors should track the full 30-patient dataset and Solid Biosciences' competing construct, which shows CK reduction, a more objective biomarker signal.
• •Biogen Tau Program Risk: Biogen's BIV-80 antisense oligonucleotide reduces tau in both CSF and PET imaging in a Phase 2 study, with early signals of slowed cognitive decline, but missed its prospectively defined primary dose-response endpoint. The decision to advance directly to Phase 3 contradicts Biogen's stated post-Aduhelm strategy of lower-risk capital allocation. Investors should treat this as a four-year binary event and size positions accordingly, given the sector's extensive history of Phase 2 Alzheimer's signals failing to replicate.